Shares of ARMO Biosciences Inc (NASDAQ:ARMO) have been given an average broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and three have issued a strong buy recommendation on the company.
Brokers have set a 12-month consensus price target of $63.25 for the company and are forecasting that the company will post ($0.45) earnings per share for the current quarter, according to Zacks. Zacks has also assigned ARMO Biosciences an industry rank of 194 out of 265 based on the ratings given to its competitors.
ARMO has been the topic of several recent analyst reports. Robert W. Baird initiated coverage on ARMO Biosciences in a report on Tuesday, February 20th. They set an “outperform” rating and a $67.00 target price on the stock. Jefferies Group initiated coverage on ARMO Biosciences in a report on Tuesday, February 20th. They issued a “buy” rating and a $61.00 price target on the stock. BMO Capital Markets initiated coverage on ARMO Biosciences in a report on Tuesday, February 20th. They issued an “outperform” rating and a $75.00 price target on the stock. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of ARMO Biosciences in a report on Tuesday, February 20th.
Shares of ARMO Biosciences (NASDAQ ARMO) traded down $3.03 during trading hours on Friday, reaching $42.99. The company had a trading volume of 174,713 shares, compared to its average volume of 227,543. ARMO Biosciences has a 1 year low of $27.00 and a 1 year high of $57.19.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-armo-biosciences-inc-armo-given-consensus-recommendation-of-buy-by-brokerages.html.
About ARMO Biosciences
ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.
Get a free copy of the Zacks research report on ARMO Biosciences (ARMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.